Canopy Growth Corporation (WEED:CA) Q3 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture: positive elements include a 22% increase in international cannabis revenue and reduced SG&A expenses. However, concerns arise from declining gross margins and unclear guidance on achieving positive EBITDA. The Q&A reveals uncertainties about veteran pricing impacts and cash utilization. The absence of a clear market cap further complicates predictions. Overall, the sentiment is balanced, resulting in a neutral outlook for the stock price movement over the next two weeks.
Key Financial Performance
Cash and Cash Equivalents $371 million, with a net cash position of $146 million. This represents the strongest net cash position since fiscal 2022. The improvement is attributed to a USD 150 million recapitalization post-quarter end, which enhanced liquidity and extended debt maturities to 2031.
Adjusted EBITDA Loss $3 million, the slimmest adjusted EBITDA loss to date. This improvement is driven by cost discipline and better execution in Canadian medical and adult-use channels.
Canada Medical Cannabis Revenue $23 million, a 15% year-over-year increase. Growth was driven by expansion in insured patient registrations, larger order sizes, and improved service levels, including faster fulfillment and reduced shipping times.
Canada Adult-Use Cannabis Revenue $23 million, an 8% year-over-year increase. Growth was supported by strength in infused pre-roll joints and new All-In-One vapes, despite revenue headwinds from disrupted retail operations in British Columbia.
International Cannabis Revenue 22% sequential increase. Growth reflects stabilization and operational improvements in the supply chain.
Cannabis Gross Margin 25%, down from 28% in the same quarter last year. The decrease is due to lower international sales and a change in sales mix within the Canadian adult-use market.
Storz & Bickel Revenue $23 million, a 45% sequential increase. Growth was driven by strong seasonal sales, including a 16% year-over-year increase in Black Friday online sales, and the first full quarter of sales for the new VEAZY device. However, gross margins decreased to 37% from 40% last year due to tariff impacts and lower volumes.
SG&A Expense Decreased 12% year-over-year. This improvement is attributed to ongoing cost-saving initiatives.
Free Cash Flow Outflow of $19 million, down from an outflow of $28 million in the same period last year. The improvement is due to reduced cash interest payments and decreased working capital movements.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New VEAZY vaporizer: Reinforces strategy around affordability and portability, contributing to a 45% sequential growth in net revenue for Storz & Bickel.
Canadian medical cannabis: Net revenue grew 15% year-over-year, marking the sixth consecutive quarter of growth. Focus on high-quality patient experience and engagement with insured patients.
Canadian adult-use cannabis: Net revenue increased 8% year-over-year, driven by pre-rolls and vapes, supported by innovation and improved retail execution.
European market: Net revenue grew 22% sequentially, with progress on EU GMP certification and focus on flower quality to serve international medical markets.
Cost savings: Achieved $29 million in annualized savings, exceeding expectations, contributing to the narrowest adjusted EBITDA loss to date of $3 million.
Balance sheet improvement: Ended the quarter with $371 million in cash and cash equivalents and a net cash position of $146 million. Completed a $150 million recapitalization post-quarter, extending debt maturities to 2031.
Proposed acquisition of MTL Cannabis: Expected to strengthen leadership in Canadian medical cannabis, enhance presence in Quebec adult-use market, and provide high-quality flower supply for domestic and international growth.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Changes: Proposed changes to the veterans reimbursement program could financially impact the company, requiring preemptive mitigation actions.
International Market Challenges: Lower sales in international markets and a change in sales mix within the Canadian adult-use market negatively impacted gross margins.
Tariff and Macro Headwinds: Storz & Bickel faced tariff-related pressures and softer demand in certain markets, impacting gross margins.
Debt and Financing Risks: Although debt maturities have been extended to 2031, reliance on tools like ATM for financing introduces potential risks depending on market conditions.
Operational Integration Risks: The proposed acquisition of MTL Cannabis requires careful integration planning to ensure operational continuity and capture strategic synergies.
Supply Chain Disruptions: Disrupted retail operations in British Columbia reduced purchases, creating revenue headwinds.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: Canopy Growth expects continued strength in Canadian adult-use cannabis driven by innovation, expanding distribution, and elevating flower capabilities. Growth in Canadian medical cannabis is also anticipated through patient growth and service excellence. International cannabis is expected to see sequential improvements in Q4 and into fiscal 2027, particularly in European markets.
Margin Projections: Improvements in cannabis gross margins are expected in Q4 and into fiscal 2027, supported by top-line revenue growth, cost-saving initiatives, and operational efficiencies.
Capital Expenditures: The company plans tighter capital allocation and improved inventory turns to support sustainable free cash flow improvements.
Business Segment Performance: Storz & Bickel is expected to face sequential top-line challenges in Q4 due to seasonal trends but will focus on VEAZY momentum and cost discipline. The MTL Cannabis acquisition is expected to contribute to net revenue, gross margin, and adjusted EBITDA improvements upon closing.
Strategic Plans: Canopy Growth aims to achieve positive adjusted EBITDA during fiscal 2027. The company is focusing on operational stability, disciplined capital allocation, and capturing synergies from the MTL Cannabis acquisition. Additionally, efforts are being made to accelerate growth in Europe, expand Storz & Bickel's reach, and enhance cultivation quality and efficiency at scale.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividends: No specific mention of a dividend program or any details related to dividends were discussed in the transcript.
Share Buyback: No specific mention of a share buyback program or any details related to share repurchase were discussed in the transcript.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the growth opportunities for the international business in the next 12 to 18 months, and how will MTL's production capabilities and EU GMP certification at Smith Falls impact this?
A:The focus is on ensuring the right supply of flower to Europe, with demand signals integrated with North American growth capabilities. By early fiscal '27, the European sales team will have over a dozen strains to sell, compared to two strains in Q3. Smith Falls is already EU GMP qualified, and a second level of certification is underway. MTL's capacity is being expanded, and operational improvements are ongoing in Europe and Germany. Confidence in achieving step-change performance in Europe next year is growing.
Q:What are the expectations for gross margin trends, particularly for cannabis, and how will MTL's higher legacy gross margin profile affect this?
A:MTL's historical margin performance exceeds Canopy's, and the company is targeting a blended gross margin of mid- to high 30s in the near term. There is potential for further improvement as the European business stabilizes and grows due to high price points in Europe. The MTL transaction is expected to be accretive to gross margin and adjusted EBITDA.
Q:Does achieving positive adjusted EBITDA during fiscal 2027 mean for the full year or just one quarter, and will it exclude MTL's contribution?
A:The company is working towards achieving adjusted EBITDA positivity as soon as possible, with expectations to reach this at some point during fiscal 2027. The timeline is influenced by cost-saving actions to counteract headwinds like veteran changes. The response did not specify whether this would be for the full year or a single quarter, nor did it clarify if it excludes MTL's contribution.
Q:Will the period of large equity issuance and dilution be over, given the current balance sheet position and net cash?
A:The company expects reduced utilization of the ATM in the coming quarters due to the current cash position but will preserve capacity for future strategic opportunities if they arise.
Q:What is the status of the proposal to reduce the cap for veterans from $8 per gram to $6 per gram, and how will it impact the domestic medical business?
A:Canopy is not in support of the reduction as it may impact veterans' care. Efforts to delay or minimize the reduction have been unsuccessful. Actions are being taken to maintain the quality of care and service for veterans and to preserve margins through cost savings. The veteran segment is a significant portion of the medical market, but exact figures were not confirmed during the call.
Q:How much cash does the company plan to keep on hand, and what are the priorities for excess cash? How much will be needed for MTL integration?
A:The company aims to maintain sufficient cash for flexibility and strategic opportunities but did not specify an exact amount. The expected cash outlay for the MTL acquisition is between $40 million and $50 million CAD.
Q:What can be done to improve sales and stabilize Storz & Bickel's performance?
A:The strategy includes expanding market penetration and usage in the U.S., accelerating innovation, and expanding price points. The entry-level VEAZY device is performing well, and there are plans to introduce devices for concentrates and distillates, which represent a large untapped market.
Q:Review of Unclear Management Responses
A:The response to whether achieving positive adjusted EBITDA during fiscal 2027 applies to the full year or just one quarter, and whether it excludes MTL's contribution, lacked clarity. Additionally, the exact portion of the medical market represented by veterans was not confirmed, and the company deferred providing precise figures.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Canada cannabis
MTL
VEAZY
acquisition
action
attention
brand
capability
capital allocation
cash position
channel
class
closing
confidence
consumer patient
cost discipline
cost saving
cultivation
date cost
debt maturity
decrease
device
flexibility
foundation
fundamental
headwind
loss date
margin improvement
phase
platform
position cannabis
quality flower
quality product
recapitalization
sale market
scale
service level
tariff
team focus
term financing
veteran
CGC Transcript
Canopy Growth Corporation (WEED:CA) Q3 2026 Earnings Call Transcript
Unknown2-6
The earnings call presents a mixed picture: positive elements include a 22% increase in international cannabis revenue and reduced SG&A expenses. However, concerns arise from declining gross margins and unclear guidance on achieving positive EBITDA. The Q&A reveals uncertainties about veteran pricing impacts and cash utilization. The absence of a clear market cap further complicates predictions. Overall, the sentiment is balanced, resulting in a neutral outlook for the stock price movement over the next two weeks.
Canopy Growth Corporation (WEED:CA) Q2 2026 Earnings Call Transcript
Positive11-7
The earnings call revealed strong financial performance in the Canadian market and improved adjusted EBITDA. Cost reduction initiatives and free cash flow improvement are positive indicators, despite some challenges in international markets. The Q&A highlighted strategic focus on cost management and potential market growth in Europe and the U.S., with no major capital investments needed. The sentiment is positive, driven by operational improvements and market expansion plans, likely resulting in a stock price increase of 2% to 8%.
Canopy Growth Corporation (CGC) Q1 2026 Earnings Call Transcript
Unknown8-8
The earnings call reflects mixed signals. Positive aspects include a 24% revenue increase and cost reduction initiatives, but challenges like declining margins, debt burden, and soft demand in key markets offset them. The Q&A highlighted gross margin improvements and potential growth in Europe, yet concerns about U.S. rescheduling and Polish supply issues persist. Overall, the financial performance and strategic outlook are balanced, leading to a neutral sentiment.
Canopy Growth Corporation (CGC) Q4 2025 Earnings Call Transcript
Unknown5-30
Despite some positive aspects like cost reduction and early loan prepayment, the earnings call highlights several concerns: declining international sales, regulatory issues in Poland, and underperformance in key markets like Ohio. The Q&A revealed management's lack of clear guidance on achieving positive EBITDA, which is concerning. The negative impacts of supply chain challenges, increased competition, and economic uncertainty further overshadow the modest revenue growth in certain areas, leading to a negative sentiment overall.
CGC Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
